Cytokinetics Q2 EPS $(0.56) Misses $(0.5) Estimate, Sales $7.137M Beat $6.99M Estimate; Results From Phase 1 Study Of Ck-274 To Be Presented At Hfsa In September 2019; Phase 2 Clinical Trial Expected To Begin In Q4
Benzinga_Newsdesk